|

CB-03-10 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Early 1: 1

Top Sponsors

  • Cosmo Technologies Ltd1

Indications

  • Subjects Considered Likely to Respond to CB-03-101
  • Advanced Refractory Solid Tumors1
  • Cancer1

California City, California1 trial

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

University of California Irvine Health Chao Family Comprehensive Cancer Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.